U.S. Stocks Rebound Significantly Higher During Dizzying Week – ( $AAPL $EPRX $GLD $INDP $JPM $LTRB $NVDA $SMMT $TSLA Rise!)

The Week in Numbers
– Dow Jones Industrial Average: Up 5% for the week, closing at 40,213. – S&P 500 Index: Gained 5.7%, finishing at 5,363. – NASDAQ: Surged 7.3%, ending at 16,724—its best weekly performance since 2022. – MSCI EAFE Index: Rose modestly by 0.5%. – 10-Year Treasury Yield: Climbed to 4.47%, marking its largest weekly rise in decades. – Gold Prices: Hit record highs above $3,200 per ounce as investors sought safe havens. The SPDR Gold Shares (GLD) closed at $297.93, +6.51% over the last 5-days.Tariffs Take Center Stage
The week began with President Trump doubling down on tariffs, notably imposing a hefty 145% rate on Chinese imports while granting other nations a temporary reprieve with a universal baseline rate of 10%. China retaliated by raising its tariffs on U.S. goods to 125%, further escalating the trade conflict and rattling markets. Midweek saw a dramatic turnaround as Trump announced a 90-day pause on tariffs for most trading partners (excluding China), sparking optimism that negotiations might lead to de-escalation. The S&P 500 soared by an unprecedented 9.5% on Wednesday—the largest single-day gain since October 2008—before retreating sharply on Thursday as fears of prolonged trade uncertainty resurfaced.Volatility Hits Historic Extremes
Market volatility reached fever pitch this week, with the Cboe Volatility Index (VIX) spiking to levels last seen during the early days of the COVID-19 pandemic. Intraday swings averaged an eye-popping 7%, far above the historical norm of 1%. While unsettling for many investors, history suggests that such extreme volatility often precedes strong forward returns for disciplined market participants.A Mixed Bag Across Asset Classes
The turbulence wasn’t confined to equities. Treasury yields surged as bond prices fell amid widespread sell-offs, reflecting investor unease about rising borrowing costs and economic uncertainty. Meanwhile, the dollar weakened against major currencies, breaking below key levels not seen in years. Gold shone brightly as the ultimate safe haven, benefiting mining stocks like Newmont and Barrick Gold.Tesla (TSLA)
Tesla’s stock had a dynamic week, finishing with a modest gain of 5.38% despite significant intraday swings. The stock rallied early in the week, reaching $274.69 on April 9 before retreating due to broader market jitters surrounding trade tensions. By Friday, Tesla closed at $252.24, reflecting investor optimism about its long-term growth prospects despite the tariff-induced turbulence. Tesla’s performance was bolstered by strong demand for its electric vehicles and the company’s ability to navigate supply chain disruptions effectively. However, concerns remain about how escalating tariffs on Chinese imports might impact raw material costs and production efficiency.
Apple (AAPL)
Apple rode the tariff rollercoaster this week but emerged stronger, posting a 6% gain on Thursday and closing Friday at $198.15, just shy of its $200 milestone. The stock rebounded sharply after the White House announced a temporary suspension of reciprocal tariffs for most nations, excluding China. This reprieve provided breathing room for Apple to stabilize its operations and regain investor confidence. Despite the rebound, Apple faces ongoing challenges due to its reliance on Chinese manufacturing. The company has accelerated efforts to reroute iPhone shipments through India, signaling a strategic pivot to mitigate risks associated with U.S.–China trade tensions. Analysts remain cautious about the long-term impact of tariffs on Apple’s margins and consumer demand.
NVIDIA (NVDA)
NVIDIA had an exceptional week, surging 17.6%, making it one of the S&P 500’s top performers.The stock benefited from optimism in the tech sector following tariff reprieves and strong demand for its AI-driven products. NVIDIA’s ability to bounce back from early-week lows reflects its robust market position and investor belief in its growth trajectory despite macroeconomic headwinds. Technical analysis suggests that NVIDIA could test higher resistance levels in the coming weeks if trade tensions ease further. Analysts anticipate that closing above key levels could signal further upside potential toward new highs within months
Earnings Season Kicks Off
Friday’s rally was buoyed by better-than-expected earnings from major banks including JPMorgan Chase (JPM, $26,20, +12.33% over the last 5-days), Morgan Stanley, and Wells Fargo. Investors shifted their focus from profit figures to insights from executives regarding the broader economic outlook amidst tariff-induced turmoil.Looking Ahead
While Friday’s gains offered some respite, markets remain far from stable. Trade negotiations will likely dominate headlines in the coming weeks as investors grapple with lingering uncertainties. The Federal Reserve has hinted at potential rate cuts to mitigate risks if economic conditions worsen further.Key Takeaways
1. Resilience Amid Chaos: Despite steep losses earlier in the week, stocks rebounded impressively, suggesting that markets may be carving out a bottom. 2. Opportunities in Volatility: Elevated fear levels could pave the way for long-term gains for patient investors who avoid knee-jerk reactions and focus on diversification and quality investments. 3. Economic Buffers Remain Strong: Healthy consumer finances and corporate balance sheets provide some cushion against potential slowdowns triggered by trade disputes. In summary, this week was a masterclass in market unpredictability—a dizzying blend of peril and promise that tested investors’ mettle while offering glimpses of brighter days ahead. As always, staying calm and focused on long-term strategies remains the best antidote to short-term noise.VP Watchlist Updates
Now let’s check out how these nuggets progressed below!
On Jan. 14, Serina announced the appointment of Karen J. Wilson to the Board of Directors. Ms. Wilson brings over three decades of leadership experiences in the life sciences sector. She currently serves as a board director for Connect Biopharma Holdings Limited, Elicio Therapeutics, Inc. and LAVA Therapeutics N.V. Previously, she held the position of Senior Vice President of Finance at Jazz Pharmaceuticals plc, where she also served as Principal Accounting Officer and Vice President of Finance. Prior to joining the Jazz Pharmaceuticals organization in February 2011, she held senior finance roles at PDL BioPharma, ViroLogic, and Novare Surgical Systems and was a consultant and auditor for Deloitte & Touche LLP. Ms. Wilson is a Certified Public Accountant and received a B.S. in Business from the University of California, Berkeley. Ms. Wilson stated, “I am excited to join Serina at such a pivotal time in its growth. I look forward to working with the talented executive team and fellow board members to help drive the company’s vision forward and make a meaningful impact in the lives of patients.”


Recent Operational and Financial Highlights
-
On October 2, 2024, the Company announced the appointment of Dr. Amanda Malone as the Chief Operating and Scientific Officer of the Company.
-
On October 10, 2024, the Company announced a poster presentation at the United European Gastroenterology Week 2024 featuring data from cohorts one through four of Eupraxia’s ongoing RESOLVE trial in EoE.
-
On October 15, 2024, the Company announced that Phase 2b data from its SPRINGBOARD trial evaluating EP-104IAR for the treatment of knee osteoarthritis was published in leading peer reviewed medical journal The Lancet Rheumatology.
-
On October 28, 2024, the Company announced two poster presentations at the American College of Gastroenterology 2024 Annual Scientific Meeting centered on EP-104GI for the treatment of EoE. One poster received a Presidential Award from the conference, which is a distinction for high quality, novel, unique, and interesting research, while the other was designated an “Abstract of Interest”.
-
On October 31, 2024, the Company announced the closing of a non-brokered private placement for gross proceeds of C$44.5 million, the appointment of Mr. Joseph Freedman to its Board of Directors, and the termination of its C$12 million convertible debt facility.
-
On November 12, 2024, the Company announced positive 12-week data from the fifth cohort of the ongoing RESOLVE trial in patients with eosinophilic esophagitis (“EoE”), noting increasingly positive data on efficacy and safety outcomes as well as emerging evidence of improved patient responses related to higher dosing levels.
-
On November 14, 2024, the Company announced a poster presentation at the American College of Rheumatology Convergence 2024 Annual Meeting covering data from Eupraxia’s Phase 2b SPRINGBOARD trial evaluating EP-104IAR for the treatment of knee osteoarthritis.
-
Subsequent to quarter end, on February 18, 2025, the Company announced the return of seasoned capital markets executive Alex Rothwell to the role of Chief Financial Officer, succeeding the retiring Bruce Cousins.
-
Subsequent to quarter end, on February 25, 2025, the Company announced positive 12-week data from the sixth cohort of the ongoing RESOLVE trial in patients with EoE noting no adverse events and continued positive data on efficacy and safety outcomes as well as further evidence of improved patient responses tied to higher dosing levels.
Fourth Quarter 2024 Financial Review
The Company incurred a net loss of $7.5 million for the three months ended December 31, 2024, versus a net loss of $10.6 million for the three months ended December 31, 2023. The decrease in net loss was primarily due to lower research and development costs and reduced other expenses incurred during the period.
The Company had cash of $33.1 million as of December 31, 2024, up from $19.3 million at the end of the fourth quarter of 2023. These funds are being used to fund clinical trials in EP-104 and the remainder of the proceeds will be used for general and administrative expenses, working capital needs and other general corporate purposes.
- One of three patients in Cohort 5 achieved complete histological remission at 12 weeks.
- Consistent improvement in patient-reported outcomes with six of six evaluable patients in the fourth and fifth cohorts experiencing a reduction in symptom (SDI1) scores at 12 weeks.
- At 24 weeks, the fourth cohort experienced the largest average reduction in SDI scores of all cohorts to date.
- The fifth cohort continued to show improved patient outcomes with the greatest percentage change in histology (EoEHSS2) scores of any cohort to date.
- Both the mean reduction in Peak Eosinophil Counts (PEC3)at four biopsy sites and the percent change in histology (EoEHSS2) scores showed a clear dose response across Cohorts 3 to 5, with Cohort 5 showing the greatest response. No serious adverse events reported in any of the five cohorts to date.
- Cohort 6 is now fully enrolled and dosed, with 12-week data anticipated in Q1 2025.


On Nov. 7, Modular Medical announced successful results from its pre-clinical GLP-1 proof of concept study. They highlighted the following: Study showed more potent weight loss and blood glucose control with the addition of a mealtime bolus of a rapid acting GLP-1 to basal delivery, Observed weight loss was 17% at 28 days, a 25% improvement over GLP-1 delivered as basal alone, & Findings suggest that pump delivery may be a viable approach to achieve GLP-1 weight and blood glucose benefits that are comparable with current treatment standards, either as initial treatment or for maintenance, while bringing personalized dosing flexibility. “With these encouraging results, we are now planning to take this concept of a synergistic basal-bolus GLP-1 combination into a human trial using our MODD1 device. We are considering both existing fast acting GLP-1s and other peptides for this trial, as we see this as a platform technology that could be used for more personalized titration for both non-responder or non-adherent patients experiencing GI and other issues with long acting GLP-1s, as well as for other specialty applications in metabolic therapies. This type of application is well suited for our MODD1 pump, given its quick training time, simple interface, high accuracy at low flow rates, reusable low-cost electronics, and a prefill-capable 3mL reservoir,” stated Jeb Besser, CEO of Modular Medical. In October, Modular’s CEO was interviewed by Carole Sullivan on the Today In Nashville program affiliated with Channel 4 WSMV. The segment is called “New Tools for Treating Diabetes by Modular Medical.” You may watch the video now at this link. On September 18, Modular Medical announced the issuance of U.S. Divisional Patent Application No. 17/968,599. “The issuance of this patent and the associated claims represent a major step in our efforts to protect the intellectual property in the MODD1 pump platform,” stated Jeb Besser, CEO of Modular Medical. “Some of the key features of our novel, low-cost and accurate insulin delivery technology are now protected by this important issued U.S. patent, which we believe represents a significant new barrier to entry. Our eight families of patents around our pump are an important part of our strategic value and market positioning, and we look forward to announcing further issuances on our portfolio in the future.” On Wednesday, September 4, Modular announced it has received U. S. Food and Drug Administration (“FDA”) clearance to market and sell its MODD1 pump in the United States. With its commercial manufacturing infrastructure substantially established, the Company anticipates the MODD1 should be available for sale in early 2025.

James (Jeb) Besser, CEO of Modular Medical (NASDAQ: MODD)


In this presentation, Dr. Newman will discuss:
-
The science behind Indaptus’ Decoy platform, a multi-immune receptor agonist designed to trigger broad innate and adaptive immune activation against tumors.
-
How the Company’s “Pulse-Prime” approach supports safe and effective anti-tumor activity in pre-clinical models, including the role of Natural Killer (NK) cells.
-
Clinical data from Indaptus’ ongoing Phase 1 trial evaluating Decoy20 in advanced solid tumors.
Advancing Decoy20 in Clinical Trials 2024 was a year of meaningful progress for Indaptus’ lead clinical candidate, Decoy20, a novel immunotherapy designed to harness both innate and adaptive immune responses. Highlights from the Company’s Phase 1 clinical trial include:
-
Second Cohort Results (March 2024): Building on the Company’s November 2023 findings, Decoy20 demonstrated a broad immune response across multiple tumor types in patients, underscoring the platform’s potential as a monotherapy.
-
Weekly-Dose Cohort Initiation (May 2024): After receiving Safety Review Committee approval, the Company dosed its first patient in the weekly-dose portion of the trial. Notably, no new, clinically significant treatment-related adverse effects were observed.
-
Higher Dose Expansion (September 2024): Following a positive safety review, Indaptus initiated a higher-dose weekly regimen, further expanding the scope of the trial to evaluate Decoy20’s safety and efficacy.
Key Scientific Presentations, Publications and Advancements Indaptus showcased Decoy20’s potential through a variety of presentations at major industry conferences and peer reviewed journals:
-
AACR Annual Meeting (April 2024): Demonstrated that Decoy activates multiple innate and adaptive immune cell types, highlighting its promise as an anti-tumor therapeutic.
-
ASCO Annual Meeting (June 2024): Shared promising preliminary results, including immune marker activation in patients with advanced solid tumors following a single dose of Decoy20.
-
STING & TLR Targeted Therapies Summit (June 2024): Dr. Michael Newman was named meeting Chairperson for the second year in a row, and presented pre-clinical and clinical Decoy data.
-
Frontiers in Immunology (November 2024): Dr. Michael Newman’s groundbreaking research on the Decoy platform was published in Frontiers in Immunology, further validating the Company’s scientific foundation and enhancing visibility within the scientific community.
-
Society for Immunotherapy of Cancer (SITC) (November 2024): Presented encouraging data highlighting consistent safety outcomes with weekly Decoy20 dosing, while demonstrating its sustained ability to activate the immune system over time.
-
Decoy platform: The Company made significant progress expanding its Decoy platform, successfully producing engineered Decoy bacteria designed to activate targeted immune pathways, enhancing its potential for broader therapeutic applications.
Clinical Supply Agreement with BeiGene
In October 2024, Indaptus achieved a key milestone when it announced a clinical supply agreement with BeiGene to advance the evaluation of Decoy20 in combination with their PD-1 checkpoint inhibitor, tislelizumab. This agreement underscores the potential versatility of the Decoy platform as a standalone therapy and in synergy with an approved immunotherapy treatment modality. This clinical combination is important because, in pre-clinical animal models, Decoy20 demonstrated significant anti-tumor synergy in combination with a PD-1 checkpoint inhibitor.
Financial Strength Indaptus raised a total of $5.5 million in 2024 through a series of strategic financing initiatives, ensuring funding to support ongoing research and development efforts into 2025.
2025 Outlook
Jeffrey Meckler, CEO of Indaptus Therapeutics, commented, “As we enter 2025, we remain committed to advancing Decoy20 through clinical trials and exploring its combination potential with BeiGene’s tislelizumab. We are excited about the progress we made in 2024 and optimistic about the transformative potential of our platform to address some of the most challenging cancers.”
Indaptus intends to maintain its commitment to robust data generation, with plans to share new findings at leading scientific forums as they become available, while actively pursuing opportunities to expand the applications of its Decoy platform.
The Company currently anticipates that it will achieve the following milestones in the first half of 2025:
-
Launch of Combination Cohort: The Company plans to open an amendment to its clinical trial to include a combination cohort evaluating Decoy20 in conjunction with the PD-1 checkpoint inhibitor, tislelizumab.
-
Expansion of Clinical Sites: Building on its progress in 2024, the Company intends to increase the number of participating clinical sites beyond the eight active locations at the end of last year, enabling broader patient enrollment.
-
Higher Dose Cohort Update: The Company plans to provide an update on the patients treated in the higher dose expansion cohort, providing insights into safety and immune activation at this dose level.
-
First Patient Dosed in Combination Cohort: The Company aims to start dosing the first patients in the combination cohort, marking an important step in evaluating Decoy20’s synergistic potential with checkpoint inhibitors.

-
HARMONIC™ trial lead-in cohort delivered impressive 86% clinical benefit rate and 43% objective response rate in never-smoker NSCLC patients, with current expansion cohort reinforcing these positive trends as enrollment accelerates in Japan and Taiwan, where 33-40% of NSCLC cases occur in never-smokers, positioning Lantern for multiple clinical readouts in 2025.
-
LP-184 received two U.S. FDA Fast Track Designations in 2024 for Glioblastoma and Triple Negative Breast Cancer, plus three additional Rare Pediatric Disease Designations, strengthening future market potential across multiple high-need indications with multi billion U.S. dollar market potential.
-
Successfully dosed multiple patient cohorts in Phase 1A clinical trials for both LP-184 and LP-284, advancing these synthetic lethal drug candidates toward drug concentration levels that may show therapeutic efficacy in several cancers of high unmet patient need and with multiple orphan and fast track FDA designations.
-
Demonstrated LP-184 synergy with checkpoint inhibitors in TNBC through MD Anderson collaboration, demonstrating ability to transform immunologically “cold” tumors into “hot” tumors by reshaping the tumor microenvironment and modulating T-cell activity in preclinical models.
-
Starlight Therapeutics unveiled recurrent GBM trial design for STAR-001 at SNO 2024, featuring innovative STAR-001+spironolactone combination regimen that leverages synthetic lethality; assembled world-class Scientific Advisory Board from Johns Hopkins, UCSF, and Memorial Sloan Kettering.
-
Showcased industry-leading capabilities in CNS therapeutic development using AI with patent-pending BBB permeability prediction algorithm with unprecedented performance –five of the top eleven rankings on Therapeutic Data Commons leaderboard and processing capabilities of 100,000 molecules per hour at industry-leading accuracy rates.
-
Unveiled innovative AI-powered ADC development module that identified 82 promising targets and 290 target-indication combinations and potentially reducing development timelines by 30-50% and preclinical costs by up to 60% compared to traditional ADC development.
-
The RADR® AI platform surpassed 100 billion oncology-specific data points in 2024, accelerating precision drug development initiatives including biomarker discovery and signature creation, identification of mechanisms of action and synergistic combination regimens, ADC optimization, and continuing to power collaborations with emerging oncology companies and centers.
-
Approximately $24 million in cash, cash equivalent


Shares of ADT Inc. (ADT), a leading provider of monitored security and automation solutions for residential and small business customers in the United States and Canada, closed at $7.82. On Feb, 27, ADT announced strong full year earnings growth; GAAP EPS up 40%, Adjusted EPS up 25%, GAAP operating cash flows up 14%, Adjusted Free Cash Flow including interest rate swaps up 42%, Record recurring monthly revenue and customer retention, Returned $423 million to shareholders and continued leverage reduction & that they are Maintaining momentum into 2025 with strong cash flow and new $500 million share repurchase plan. ADT will release its Q1/2025 results on Thursday, April 2025.
On Jan. 22, ADT announced the appointment of Thomas Gartland to the Company’s Board of Directors as an additional independent director. In conjunction with his appointment, Gartland will join the Board’s Audit Committee. Gartland is chairman and chief executive officer of Montway Auto Transport, a privately held auto transport company, and has held this position since 2023. Prior to Montway, Gartland served as executive chairman of Scan Global Logistics and as president, North America, for Avis Budget Group. Gartland serves on the boards of Xenia Hotels & Resorts, Inc. and ABM.

- Mpox remains a global public health crisis in 2025, with Clade 1b exhibiting higher transmissibility and severity than Clade 2.
- The Democratic Republic of the Congo (DRC) is the epicenter, with over 60,000 suspected cases and 1,300 deaths in 2024 alone.
- The virus has now spread to multiple countries, including the U.S., Canada, and Europe, raising concerns about global containment.
- The U.S. has confirmed four Clade 1b cases (California, Georgia, New Hampshire, and New York), prompting the need for urgent action.
- The current vaccine supply chain is inadequate, relying heavily on a single non-U.S. manufacturer.
- Delays in vaccine distribution, high costs, and limited production capacity have exacerbated the crisis, particularly in Africa, where vaccine stockpiles remain largely unused due to logistical and political challenges.
- GEO-MVA, the GeoVax Mpox vaccine candidate is advancing to clinical evaluation, anticipated for H2 ’25.
-
Scientific Expertise: Professor Teresa Lambe, a principal investigator at the Oxford Vaccine Group, recently joined GeoVax’s Scientific Advisory Board. Professor Lambe played a pivotal role in the development of the Oxford/AstraZeneca COVID-19 vaccine and has extensive experience in vaccine design and evaluation.
-
Manufacturing Partnerships: GeoVax maintains an existing contract development and manufacturing organization (CDMO) relationship with Oxford Biomedica PLC (Oxford, UK), as well as additional collaborations with Oxford Biomedica (France), with facilities in Strasbourg and Lyon.
-
Technology Licensing: The Company has a broad licensing agreement with ProBioGen AG (Berlin, Germany) to utilize their AGE1 continuous avian cell line for the manufacture of MVA vaccines.
-
European Collaborations: GeoVax currently collaborates with multiple European-based service providers and UK academic partners, reinforcing the strategic rationale for establishing a presence within the region.
To support this initiative, GeoVax is working closely with Professor Teresa Lambe and clinical investigators and scientists in Oxford and other academic centers across the UK to develop preclinical, translational, and clinical projects supporting its pipeline. Additionally, Dr. Deborah Spencer, a highly regarded expert in industry-academic partnerships and public health development, has recently been retained to facilitate and coordinate initiatives in the UK and Europe. Establishing a strategic presence in Europe will support GeoVax’s infectious disease vaccine development efforts and play a key role in advancing Gedeptin(R), the Company’s lead immuno-oncology candidate. Currently in clinical development for the treatment of advanced head and neck cancers, Gedeptin is anticipated to be further developed for use with immune checkpoint inhibitors as a potential treatment for various other solid tumors. GeoVax holds worldwide rights to Gedeptin for all indications.

QUOTE OF WEEK
“All change is not growth, as all movement is not forward.” – Ellen Glasgow
Investing & Inspiration
- “All change is not growth, as all movement is not forward.” – Ellen Glasgow
- “If you’re going through hell, keep going.” – Winston Churchill
- “A will finds a way.” – Orison Swett Marden
- “You can never plan the future by the past.” – Edmund Burke
- “If you live to be a hundred, I want to live to be a hundred minus one day so I never have to live without you.” – A. A. Milne
- “I am still learning.” – Michelangelo
- “Every failure is a step to success.” – William Whewell
- “I attribute my success to this – I never gave or took any excuse.” – Florence Nightingale
- “A man should always consider how much he has more than he wants.” – Joseph Addison
- “Once you bring life into the world, you must protect it. We must protect it by changing the world.” – Elie Wiesel
- “No one has a greater asset for his business than a man’s pride in his work.” – Hosea Ballou
- “In three words I can sum up everything I’ve learned about life: it goes on.” – Robert Frost
- “The most worth-while thing is to try to put happiness into the lives of others.” – Robert Baden-Powell
- “A good beginning makes a good end.” – Louis L’Amour
- “Humanity is acquiring all the right technology for all the wrong reasons.” – R. Buckminster Fuller
- “There is a certain enthusiasm in liberty, that makes human nature rise above itself, in acts of bravery and heroism.” – Alexander Hamilton
- “You don’t take a photograph, you make it.” – Ansel Adams
- “The less we deserve good fortune, the more we hope for it.” – Lucius Annaeus Seneca
- “Art is the right hand of Nature. The latter has only given us being, the former has made us men.” – Friedrich Schiller
- “To begin, begin.” – William Wordsworth
- “Nature does not hurry, yet everything is accomplished.” – Lao Tzu
- “The end of labor is to gain leisure.” – Aristotle
- “People are not disturbed by things, but by the view they take of them.” – Epictetus
- “Have patience. All things are difficult before they become easy.” – Saadi
- “The future rewards those who press on. I don’t have time to feel sorry for myself. I don’t have time to complain. I’m going to press on.” – Barack Obama
- “The traveler sees what he sees, the tourist sees what he has come to see.” – Gilbert K. Chesterton
- “The only true wisdom is in knowing you know nothing.” – Socrates
- “Courage is knowing what not to fear.”– Plato
- “The home is the chief school of human virtues.” – William Ellery Channing
- “Be brave. Take risks. Nothing can substitute experience.” – Paulo Coelho
- “There are no shortcuts in evolution.” – Louis D. Brandeis
- “A friend may well be reckoned the masterpiece of nature.” – Ralph Waldo Emerson
- “Nature uses as little as possible of anything.” – Johannes Kepler
- “Every new beginning comes from some other beginning’s end.” – Seneca
- “Nothing ever becomes real till it is experienced.” – John Keats
- “Nobody who ever gave his best regretted it.” – George Halas
- “Honest disagreement is often a good sign of progress.” – Mahatma Gandhi
- “A leader is one who knows the way, goes the way, and shows the way.” – John C. Maxwell
- “They always say time changes things, but you actually have to change them yourself.” – Andy Warhol
- “The secret of happiness is something to do.” – John Burroughs
- “The world of reality has its limits; the world of imagination is boundless.”
- “You begin with the possibilities of the material.” – Robert Rauschenberg
- “The only Zen you can find on the tops of mountains is the Zen you bring up there.” – Robert M. Pirsig
- “Leadership is the capacity to translate vision into reality.” – Warren Bennis
- “A man should always consider how much he has more than he wants.” – Joseph Addison
- “Happiness is good health and a bad memory.” – Ingrid Bergman
- “We pass through this world but once.” – Stephen Jay Gould
- “Christmas waves a magic wand over this world, and behold, everything is softer and more beautiful.” – Norman Vincent Peale
- “Nothing can have value without being an object of utility.” – Karl Marx
- “Always turn a negative situation into a positive situation.” – Michael Jordan
- “Courage is found in unlikely places.” – J. R. R. Tolkien
- “One that would have the fruit must climb the tree.” – Thomas Fuller
- “Someone is sitting in the shade today because someone planted a tree a long time ago.” – Warren Buffett
- “We relish news of our heroes, forgetting that we are extraordinary to somebody too.” – Helen Hayes
- “A life spent making mistakes is not only more honorable, but more useful than a life spent doing nothing.” – George Bernard Shaw
- “Everything in the world may be endured except continual prosperity.” – Johann Wolfgang von Goethe
- “Nine-tenths of wisdom is being wise in time.” – Theodore Roosevelt
- “Time is money.” – Benjamin Franklin
- “Change before you have to.” – Jack Welch
- “Our deeds determine us, as much as we determine our deeds.” – George Eliot
- “The Universe is under no obligation to make sense to you.” – Neil deGrasse Tyson
- “Care and diligence bring luck.” – Thomas Fuller
- “Nobody made a greater mistake than he who did nothing because he could do only a little.” – Edmund Burke
- “A man who is a master of patience is master of everything else.” – George Savile
- “Once you replace negative thoughts with positive ones, you’ll start having positive results.” – Willie Nelson
- “Endurance is nobler than strength, and patience than beauty.” – John Ruskin
- “Act as if what you do makes a difference. It does.” – William James
- “Let us be grateful to people who make us happy, they are the charming gardeners who make our souls blossom.” – Marcel Proust
- “Strength and growth come only through continuous effort and struggle.” – Napoleon Hill
- “Science may never come up with a better office communication system than the coffee break.” – Earl Wilson
- “If everyone is moving forward together, then success takes care of itself.” – Henry Ford
- “Hope is like the sun, which, as we journey toward it, casts the shadow of our burden behind us.”– Samuel Smiles
- “Patriotism is supporting your country all the time, and your government when it deserves it.” – Mark Twain
- “What would life be if we had no courage to attempt anything?” – Vincent Van Gogh
- “The biggest risk is not taking any risk… In a world that is changing really quickly, the only strategy that is guaranteed to fail is not taking risks.” – Mark Zuckerberg
- “Our lives improve only when we take chances – and the first and most difficult risk we can take is to be honest with ourselves.” – Walter Anderson
- “Action is the foundational key to all success.” – Pablo Picasso
- “Success is never final, failure is never fatal. It’s courage that counts.” – John Wooden
- “Innovation distinguishes between a leader and a follower.” – Steve Jobs
- “All the art of living lies in a fine mingling of letting go and holding on.” – Havelock Ellis
- “The size of your success is measured by the strength of your desire; the size of your dream; and how you handle disappointment along the way.” – Robert Kiyosaki
- “O, wind, if winter comes, can spring be far behind?” – Percy Bysshe Shelley
- “Patience is a virtue, and I’m learning patience. It’s a tough lesson.” – Elon Musk
- “Be true to your work, your word, and your friend.” – John Boyle O’Reilly
- “Believe in yourself! Have faith in your abilities! Without a humble but reasonable confidence in your own powers you cannot be successful or happy.” – Norman Vincent Peale
- “Surprise is the greatest gift which life can grant us.” – Boris Pasternak
- “Logic will get you from A to B. Imagination will take you everywhere.” – Albert Einstein
- “It is the fight alone that pleases us, not the victory.” – Blaise Pascal
- “Do exactly what you would do if you felt most secure.” – Meister Eckhart
- “Life lived for tomorrow will always be just a day away from being realized.” – Leo Buscaglia
- “Wisdom is oftentimes nearer when we stoop than when we soar.” – Wordsworth
- “Take chances, make mistakes. That’s how you grow. Pain nourishes your courage. You have to fail in order to practice being brave.” – Mary Tyler Moore
- “A single twig breaks, but the bundle of twigs is strong.” – Tecumseh
- “If one does not know to which port one is sailing, no wind is favorable.” – Lucius Annaeus Seneca
- “There is little that can withstand a man who can conquer himself.” – Louis XIV
- “The limits of the possible can only be defined by going beyond them into the impossible.” – Arthur C. Clarke
- “Be faithful in small things because it is in them that your strength lies.” – Mother Teresa
- “The future rewards those who press on. I don’t have time to feel sorry for myself. I don’t have time to complain. I’m going to press on.” – Barack Obama
- “By three methods we may learn wisdom: First, by reflection, which is noblest; Second, by imitation, which is easiest; and third by experience, which is the bitterest.” – Confucius
- “No man was ever wise by chance.” – Lucius Annaeus Seneca
- “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
- “It is not in the stars to hold our destiny but in ourselves.” – William Shakespeare
- “It does not matter how slowly you go as long as you do not stop.” – Confucius
- “I want to put a ding in the universe.” – Steve Jobs
- “Research is creating new knowledge.” – Neil Armstrong
- “The reward for work well done is the opportunity to do more.” – Jonas Salk
- “Man is a creative retrospection of nature upon itself.” – Karl Wilhelm Friedrich Schlegel
- “There’s something about taking a plow and breaking new ground. It gives you energy.” – Ken Kesey
- “Success seems to be largely a matter of hanging on after others have let go.” – William Feather
- “The essential conditions of everything you do must be choice, love, passion.” – Nadia Boulanger
- “More business is lost every year through neglect than through any other cause.” – Rose Kennedy
- “Give me a lever long enough and a fulcrum on which to place it, and I shall move the world.” – Archimedes
- “A person who won’t read has no advantage over one who can’t read.” – Mark Twain
- “The best way out is always through.” – Robert Frost
- “Start by doing what’s necessary; then do what’s possible; and suddenly you are doing the impossible.” – Francis of Assisi
- “Without labor nothing prospers.” – Sophocles
- “Intellectuals solve problems, geniuses prevent them.” – Albert Einstein
- “This is the precept by which I have lived: Prepare for the worst; expect the best; and take what comes.” – Hannah Arendt
- “The best and most beautiful things in the world cannot be seen or even touched – they must be felt with the heart.” – Helen Keller
- “He who is brave is free.” – Lucius Annaeus Seneca
- “When something is important enough, you do it even if the odds are not in your favor.” – Elon Musk
- “I choose a block of marble and chop off whatever I don’t need.” – Auguste Rodin
- “Hope is the only bee that makes honey without flowers.” – Robert Green Ingersoll
- “He who knows that enough is enough will always have enough.” – Lao Tzu
- “Plans to protect air and water, wilderness and wildlife are in fact plans to protect man.” – Stewart Udall
- “In order to carry a positive action we must develop here a positive vision.” – Dalai Lama
- “A hero is someone who understands the responsibility that comes with his freedom.” – Bob Dylan
- “Inflation destroys savings, impedes planning, and discourages investment. That means less productivity and a lower standard of living.” – Kevin Brady
- “If we give something positive to others, it will return to us. If we give negative, that negativity will be returned.” – Allu Arjun
- “A good plan violently executed now is better than a perfect plan executed next week.” ~ George S. Patton
- “You must do the things you think you cannot do.”- Eleanor Roosevelt
- “Success is dependent on effort.” – Sophocles
- “Nobody who ever gave his best regretted it.” – George Halas
- “Lots of people want to ride with you in the limo, but what you want is someone who will take the bus with you when the limo breaks down.” ~ Oprah Winfrey
- “And when I breathed, my breath was lightning.” – Black Elk
- “Moderation is the silken string running through the pearl chain of all virtues.” – Joseph Hall
- “You are the sum total of everything you’ve ever seen, heard, eaten, smelled, been told, forgot – it’s all there. Everything influences each of us, and because of that I try to make sure that my experiences are positive.” – Maya Angelou
- “If you want a guarantee, buy a toaster.” – Clint Eastwood
- “We are an impossibility in an impossible universe.” – Ray Bradbury
- “If you think in terms of a year, plant a seed; if in terms of ten years, plant trees; if in terms of 100 years, teach the people.” – Confucius
- “I’d rather attempt to do something great and fail than to attempt to do nothing and succeed.” – Robert H. Schuller
- “Do your little bit of good where you are; it’s those little bits of good put together that overwhelm the world.” Desmond Tutu
- “It takes considerable knowledge just to realize the extent of your own ignorance.” – Thomas Sowell
- “Do not dwell in the past, do not dream of the future, concentrate the mind on the present moment.” – Buddha”
- Surprise is the greatest gift which life can grant us.” – Boris Pasternak
- “Trust in dreams, for in them is hidden the gate to eternity.” – Khalil Gibran
- “Always be yourself, express yourself, have faith in yourself, do not go out and look for a successful personality and duplicate it.” – Bruce Lee
- “All life is an experiment. The more experiments you make the better.” – Ralph Waldo Emerson
- “There are no secrets to success. It is the result of preparation, hard work, and learning from failure.” – Colin Powell
- “There is more to life than increasing its speed.” – Mahatma Gandhi
- “Your attitude is like a box of crayons that color your world. Constantly color your picture gray, and your picture will always be bleak. Try adding some bright colors to the picture by including humor, and your picture begins to lighten up.” – Allen Klein
- “Definiteness of purpose is the starting point of all achievement.” – W. Clement Stone
- “Success usually comes to those who are too busy to be looking for it.” – Henry David Thoreau
- “In matters of truth and justice, there is no difference between large and small problems, for issues concerning the treatment of people are all the same.” – Albert Einstein
- “Life is too short for long-term grudges.” – Elon Musk
- “There cannot be a crisis next week. My schedule is already full.” – Henry Kissinger
- “Success consists of getting up just one more time than you fall.” – Oliver Goldsmith
- “The Earth is the cradle of humanity, but mankind cannot stay in the cradle forever.” – Konstantin Tsiolkovsky
- “Ours is a world of nuclear giants and ethical infants. We know more about war that we know about peace, more about killing that we know about living.” – Omar N. Bradley
- “Beauty surrounds us, but usually we need to be walking in a garden to know it.” – Rumi
- “But man is not made for defeat. A man can be destroyed but not defeated.” – Ernest Hemingway
- “Don’t watch the clock; do what it does. Keep going.” – Sam Levenson
- “Let there be work, bread, water and salt for all.” – Nelson Mandela
- “The social object of skilled investment should be to defeat the dark forces of time and ignorance which envelope our future.” – John Maynard Keynes
- “A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
- “I know not with what weapons World War III will be fought, but World War IV will be fought with sticks and stones.” – Albert Einstein
- “It is the fight alone that pleases us, not the victory.” – Blaise Pascal
- “If you can’t describe what you are doing as a process, you don’t know what you’re doing.” – W. Edwards Deming
- “Never interrupt your enemy when he is making a mistake.” – Napoleon Bonaparte
- “Be sure you put your feet in the right place, then stand firm.” – Abraham Lincoln
- “Without investment there will not be growth, and without growth there will not be employment.” – Muhtar Kent
- “You have to do your own growing no matter how tall your grandfather was.” – Abraham Lincoln
- “Victory has a thousand fathers, but defeat is an orphan.” – John F. Kennedy
- “Delete the negative; accentuate the positive!” – Donna Karan
- “It’s crazy how fast time flies and how things progress.” – Nathan Chen
- “The world is a dangerous place to live; not because of the people who are evil, but because of the people who don’t do anything about it.” – Albert Einstein
- “Life isn’t about finding yourself. Life is about creating yourself.” – George Bernard Shaw
- “Everything has beauty, but not everyone sees it.” – Confucius
- “A man must be big enough to admit his mistakes, smart enough to profit from them, and strong enough to correct them.” – John C. Maxwell
- “Walking with a friend in the dark is better than walking alone in the light.” – Helen Keller
- “A man who dares to waste one hour of time has not discovered the value of life.” – Charles Darwin
- “The greater danger for most of us lies not in setting our aim too high and falling short; but in setting our aim too low, and achieving our mark.” – Michelangelo
- “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
- “I like to encourage people to realize that any action is a good action if it’s proactive and there is positive intent behind it.” – Michael J. Fox
- “Nothing is impossible, the word itself says ‘I’m possible’!” – Audrey Hepburn
- “But investment in space stimulates society, it stimulates it economically, it stimulates it intellectually, and it gives us all passion.” – Bill Nye
- “Bitcoin, in the short or even long term, may turn out be a good investment in the same way that anything that is rare can be considered valuable. Like baseball cards. Or a Picasso.” – Andrew Ross Sorkin
- “Life is a tragedy when seen in close-up, but a comedy in long-shot.” – Charlie Chaplin
- “No matter what you’re going through, there’s a light at the end of the tunnel and it may seem hard to get to it but you can do it and just keep working towards it and you’ll find the positive side of things.” – Demi Lovato
- “Infrastructure investment in science is an investment in jobs, in health, in economic growth and environmental solutions.” – Oren Etzioni
- “Educating our children and giving them the skills they need to compete in a global economy is a smart investment in our country’s future.” – Sheldon Whitehouse
- “Know thy self, know thy enemy. A thousand battles, a thousand victories.” – Sun Tzu
- “If one does not know to which port one is sailing, no wind is favorable.” – Lucius Annaeus Seneca
- “Beware of missing chances; otherwise it may be altogether too late some day.” – Franz Liszt
- “The sofa is a really important investment for anybody, and I don’t mean financially. You need to find a really great sofa that can transition with you, and you can build from there.” – Jeremiah Brent
- “There is no investment you can make which will pay you so well as the effort to scatter sunshine and good cheer through your establishment.” – Orison Swett Marden
- “Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.” – Marie Curie
- “There is little that can withstand a man who can conquer himself.” – Louis XIV
- “In tennis, you strike a ball just after the rebound for the fastest return. It’s the same with investment.” – Masayoshi Son
- “A camel makes an elephant feel like a jet plane.” – Jackie Kennedy
- “The advance of technology is based on making it fit in so that you don’t really even notice it, so it’s part of everyday life.” – Bill Gates
- “Success depends upon previous preparation, and without such preparation there is sure to be failure.” – Confucius, Chinese
- “Coming together is a beginning; keeping together is progress; working together is success.” – Edward Everett Hale
- “Never do anything against conscience even if the state demands it.”– Albert Einstein
- “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey
- “The true measure of a man is how he treats someone who can do him absolutely no good.” – Samuel Johnson
- “In my view, the biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital. Not only is the mere drop in stock prices not risk, but it is an opportunity. Where else do you look for cheap stocks?” – Li Lu
- “A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
- “The best preparation for tomorrow is doing your best today.” – H. Jackson Brown, Jr.
- “Friendship marks a life even more deeply than love. Love risks degenerating into obsession, friendship is never anything but sharing.” – Elie Wiesel
- “Investing in women’s lives is an investment in sustainable development, in human rights, in future generations – and consequently in our own long-term national interests.” – Liya Kebede
- “Success isn’t measured by money or power or social rank. Success is measured by your discipline and inner peace.” – Mike Ditka
- “No matter how many goals you have achieved, you must set your sights on a higher one.” – Jessica Savitch
- “Start where you are. Use what you have. Do what you can.”– Arthur Ashe
- “The secret of getting ahead is getting started.” – Mark Twain
- “The amount of work and the amount of both physical and emotional investment it takes to get to the top.” – Drew Bledsoe
Post View Count : 501